INFLUENZA A VIRUSES (IAV) are a major cause of morbidity and mortality worldwide. The innate immune response plays a key role defense against IAV in the first few days after infection (26) . Treatment options include amantadines and neuraminidase inhibitors, although resistance has been observed with increasing frequency (4) . An additional problem is that some of the serious illness caused by IAV may relate to inflammatory injury. Other frequent complications are bacterial superinfection and exacerbation of reactive airways disease (2, 12) . Pandemic IAV strains pose particular problems because antigenically, they are radically different from prior seasonal strains. In addition, pandemic strains in general show greater pathogenicity than seasonal strains.
The innate host response to IAV is very important because it may determine the intensity of the inflammatory response to viral infection, inform the adaptive immune response, and account for differences in pathogenicity of pandemic vs. seasonal strains of IAV (26) . Surfactant protein D (SP-D), a collectin synthesized by respiratory epithelial cells, appears to play particularly important roles in this innate response. SP-D is the predominant mediator of antiviral activity against seasonal strains of IAV in human bronchoalveolar lavage (15) , and mice lacking SP-D have significantly greater viral replication and illness from certain seasonal strains of IAV (18) . Notably, pandemic IAV strains (including that in 2009), or recombinant viral strains containing just the hemagglutinin (HA) of a pandemic strain along with the other segments of a seasonal virus, are resistant to native SP-D (19, 21) . Pandemic and avian strains in general have limited glycosylation on their HA head regions, which likely accounts for their resistance to inhibition by SP-D. Resistance of pandemic viral strains to inhibition by SP-D or the related collectin, mannose-binding lectin (MBL) (27) , is likely one factor in their increased pathogenicity (13) . SP-D and MBL have been categorized as ␤-inhibitors, which refers to IAV inhibitors that act by binding to virus-associated carbohydrates in a calcium-dependent manner. Another category of inhibitors are ␥-inhibitors that provide decoy ligands to which the HA may bind. This process is not calciumdependent. Some ␥-inhibitors (e.g., H-ficolin) (27) are effective against pandemic H1N1 IAV strains, whereas others either do not inhibit (e.g., pentraxins) (19) or have very low effectiveness as inhibitors (e.g., surfactant protein A or SP-A) (27) .
Modification of innate defense mediators such as collectins and antimicrobial peptides can result in more effective inhibition of IAV. We and others have studied the activity of recombinant versions of SP-D composed of only the neck and carbohydrate recognition domains (NCRDs) of the molecule, without the extended collagen domain or NH 2 -terminus (3, 5, 7, 16, 20, 28) . The advantages of such NCRDs include greater ability to directly compare activity between different mutants (i.e., by eliminating the complicating effects of variable higherorder multimerization conferred by the collagen and NH 2 -terminal domains), the ability to crystallize NCRDs and perform structure-function analysis, and greater ease of production. The NCRD of wild-type human SP-D (wild-type NCRD) has glycan binding activity and protective effects in mouse models of allergy and respiratory syncytial virus infection, but completely lacks activity against IAV. This appears to result from a loss of cooperative binding effects afforded by having multiple trimeric NCRD heads on the full-length SP-D molecule (25, 28) . We have reported, however, that mutating residues surrounding the lectin site of the SP-D NCRD confers increased viral binding and neutralizing activity. In particular, a mutant form of the trimeric carbohydrate recognition domain (i.e., NCRD) of SP-D with combinatorial substitutions at the 325 and 343 positions (D325AϩR343V) has greatly increased activity against seasonal IAV in vitro and in vivo (8) .
In this paper we report on additional mutant NCRD preparations, including an additional double mutant, D325SϩR343V, which substitutes a serine rather than an alanine at position 325. We show that the D325SϩR343V mutant has stronger antiviral activity than D325AϩR343V against the 1968 H3N2 pandemic strain and protects mice from mortality caused by this strain. The double-mutant NCRDs strongly aggregate Aichi68 as revealed by light absorbance and confocal microscopy. Most importantly, we show that the double-mutant NCRDs have the ability to inhibit pandemic H1N1 strains from 2009 and 1918, both of which are not inhibited by native SP-D.
MATERIALS AND METHODS
Virus preparations. The Philippines 82/H3N2 (Phil82) and Brazil 78/H1N1 (Braz78) strains and their bovine serum inhibitor-resistant variants (Phil82BS and Braz78BS, respectively) were kindly provided by Dr. E. Margot Anders (University of Melbourne, Melbourne, Australia). The Aichi68 H3N2 (Aichi68) strain was obtained from American Type Culture Collection (ATCC, Manassas, VA). These IAV strains were grown in the chorioallantoic fluid of 10-day-old chicken eggs and purified on a discontinuous sucrose gradient as previously described (14) . The virus was dialyzed against PBS to remove sucrose, aliquoted, and stored at Ϫ80°C until needed. After thawing, the viral stocks contained ϳ5 ϫ 10 8 infectious focusforming units/ml. The California 2009 H1N1 pandemic strain (Cal09) and the New York 2001 H1N1 (NY01) seasonal strains were prepared by reverse genetics as described (21, 27) . Additional strains related to the 2009 pandemic strain were developed by reverse genetics, including a strain containing only the HA gene of the pandemic Mexico 2009 H1N1 combined with the other seven genes of NY01 (Mex 1:7) and an additional strain containing the HA and neuraminidase (NA) of Mexico 2009 (Mex 2:6). Finally, a strain containing the HA of the 1918 pandemic H1N1 was also used. The reverse genetics-derived strains were grown in MDCK cells as described. Table 1 shows the positions of glycan attachment sites on the head region of the HA of the viral strains used in this paper. Note that the only strain that has been subjected to formal glycan analysis is the Phil82 H3N2 strain (Ref. 7 and our unpublished data), and location of glycans on the other strains was predicted on the basis of amino acid sequence.
Collectin preparations. Recombinant human SP-D dodecamers were produced in CHO cells as previously described (11) . Trimeric NCRD fusion proteins consist of the neck domain and carbohydrate recognition domains of SP-D combined with NH 2-terminal tags that contain a His-tag and S-protein binding site that permit purification and/or detection (PMID 15711012). R343V, D325A, and D325AϩR343V were produced and characterized as previously described (5, 7). D325S, D325V, and D325SϩR343V fusion proteins were produced in the same way. All showed a single major band of appropriate size by SDS-PAGE and demonstrated the expected decrease in mobility on reduction, consistent with appropriate formation of intrachain disulfide bonds. The endotoxin level of all SP-D preparations was 0.1 to ϳ0.5 EU/ml (Limulus Lysate Assay; Cambrex, Walkersville, MD).
HA inhibition assay. HA inhibition was measured by serially diluting collectins in round-bottom 96-well plates (Serocluster UVinyl plates; Costar, Cambridge, MA) with PBS containing calcium and magnesium as a diluent and human type O red cells as described (29) .
Measurement of viral aggregation. Viral aggregation caused by collectins was measured by assessing light transmission through stirred suspensions of IAV. This was performed using a Perkin Elmer Lambda 35 UV/Vis spectrophotometer. In addition, viral aggregation was assessed using electron microscopy as described (27) . Fluorescent focus assay and plaque assay of IAV infectivity. MDCK cell monolayers were prepared in 96-well plates and grown to confluency. These layers were then infected with diluted IAV preparations for 45 min at 37°C in PBS (with 2 mM calcium and magnesium). MDCK cells were tested for the presence of IAV-infected cells after 7 h of virus addition using a monoclonal antibody directed against the influenza A viral nucleoprotein (provided by Dr. Nancy Cox, Centers for Disease Control and Prevention, Atlanta, GA) as previously described (29) . IAV was preincubated for 30 min at 37°C with various concentrations of collectins or control buffer, followed by addition of these viral samples to the MDCK cells. Similar assays were also performed using undifferentiated primary human tracheobronchial epithelial (HTBE) cells obtained from ATCC and cultured according to the manufacturer's recommendations. In some experiments, 10 mg/ml of maltose was added to D325AϩR343V during the incubation with virus.
The plaque reduction neutralization assay was performed as previously described (21) . MDCK cells were seeded into 24-well plates and grown to confluency. Following sequential twofold dilution of D325AϩR343V and wild-type human NCRD (hNCRD) proteins (8 g/ml) in DPBS (up to a final concentration of 15 ng/ml), each dilution was mixed with an equal volume of virus that corresponded to 20 -30 plaques per well. Mixed samples (100 l) were first preincubated at room temperature for 45-60 min and then layered onto MDCK cells. Each sample was tested in three wells. As a control, virus alone without NCRDs was used. Following incubation at 37°C for 1 h, samples were aspirated and cells were washed with PBS. Subsequently, cells were overlaid with 2% agar (wt/vol) in 2ϫ DMEM. Visualization of plaques occurred 48 h later using crystal violet.
Measurement of viral RNA. RNA for the viral M protein was measured using real-time PCR. A549 cells were infected with the Cal09 virus strain incubated for 30 min at 37°C with or without various doses of NCRDs. RNA extraction occurred at 45 min and 24 h postinfection using a Magmax viral RNA isolation kit (Applied Biosytems, Carlsbad, CA) according to the manufacturer's instructions. Both lysed cells and the cell supernatant were used for extraction. Viral RNA was also extracted from different concentrations of virus with known infectious particles per milliliter, which was used as a standard series for each experiment. RNA was reverse-transcribed using TaqMan reverse transcription reagents (Applied Biosytems). The reaction mix and the cycle conditions were as per the manufacturer's instructions. For real-time PCR, primers specific for IAV M protein (forward, AGA CCA ATC CTG TCA CCT CTGA; reverse, CTG CAG TCC TCG CTC ACT) were used. The primers and TaqMan-labeled probes with nonfluorescent minor groove binder (MGB) moieties were designed manually using the Primer Express software version 3.0 (Applied Biosystems) and were also synthesized by Applied Biosystems. The assay sequences were examined for specificity using nucleotide BLAST. The experiment was performed in a 7500 real-time PCR system (Applied Biosytems) using a volume of 20 l containing 2 l of template cDNA, 0.9 M primer, 0.25 M of 6-FAM dye-labeled TaqMan MGB probe (6-FAM-ATT TGT GTT CAC GCT CAC CGT G-MGB), and 1ϫ TaqMan Universal PCR master mix (Applied Biosytems). Thermal cycling proceeded at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, 60°C for 1 min, and 72°C for 30 s. For calculation of infectious particles per milliliter from the cycle threshold (C t) values, we first plotted a standard curve using the known log10 values of focus forming units per milliliter and corresponding Ct values. The Ct values of samples were converted to log10 values of infectious particles/ml (x) by using the formula y ϭ mx ϩ c, where y is the Ct value, m is the slope, and c is the intercept. Slope and intercept were calculated from the standard curve by using Micosoft Excel. Log10 values of infec- tious particles per milliliter were converted to infectious particles per milliliter by performing an anti-log (10^log 10 value).
Confocal microscopy. For these experiments, the Aichi68 strain of IAV was labeled with Alexa Fluor 594. The Alexa Fluor 594 carboxylic acid, succinimidyl ester labeling kit was purchased from Molecular Probes, and labeling was carried out using the manufacturer's recommendations with some modifications. In brief, concentrated virus stock was incubated with the Alexa Fluor in sodium bicarbonate buffer (pH 8.3) for 1 h at room temperature. The preparation was then dialyzed overnight against PBS at 4°C. After this procedure there was no reduction in viral HA titer. A549 or MDCK cells were preincubated with the labeled virus for 45 min, followed by washing and fixation using 1% paraformaldehyde. Prior to this the IAV was either preincubated with control buffer or NCRDs for 30 min at 37°C in the same manner as in the infectious focus assay. Wheat germ agglutinin (WGA)-Oregon Green 488 (4 g/ml) and DAPI 350 were used to stain the cell membrane and nucleus, respectively. Confocal photographs were taken with a Zeiss LSM510 (LSEB) at ϫ100 resolution.
Murine model of IAV infection. In vivo mortality studies were conducted with 10-to 16-wk-old female DBA/2J mice (The Jackson Laboratory, Bar Harbor, ME). Mice were lightly anesthetized with isoflurane. Fifty microliters of Aichi68 stock in DPBS with Ca 2ϩ and Mg 2ϩ ions was coadministered via oropharyngeal aspiration with or without 20 g/mouse D325S/R343V NCRD or wild-type hNCRD. Viral titers of the inoculum were 1.5 ϫ 10 3 viral particles/ml as assessed by real-time quantitation (AD502; iGentBio, San Diego, CA). Mice were weighed every other day and checked daily for vital status. All animals were maintained in a specific pathogen-free facility and were handled according to an institutional animal care and use committee-approved protocol and National Institutes of Health guidelines. In some experiments whole lungs were harvested 72 h after viral infection (n ϭ 4/group). The tissue was homogenized in DPBS without Ca 2ϩ and Mg 2ϩ and spun at 3,000 g for 10 min. The supernatant was collected, aliquoted, and stored at Ϫ80°C.
Assessment of viral clearance in vivo. Total RNA was isolated from infected mouse lung homogenate by using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), and viral RNA was purified by the Viral RNA Spin Protocol (Qiagen) and stored at Ϫ20°C. Realtime fluorescence detection of viral RNA was performed in a single, closed-tube system (ABI Prism 7300; Applied Biosystems) using the Bio-Rad One-Step RT-PCR enzyme mix (Bio-Rad, Hercules, CA) and the Influenza A Virus Detection Kit (AD502; iGentBio). The cycling parameters were 10 min at 10°C, 5 min at 95°C, and 45 cycles of 15 s at 95°C and 60 s at 60°C. Control D325A+R343V D325S+R343V hnCRD Fig. 4 . Aggregation and reduction in viral particle numbers of Aichi68 after preincubation with D325AϩR343V. These experiments were performed using confocal microscopy and MDCK cells. The ability of D325AϩR343V to induce viral aggregation and reduce viral particle numbers is most evident in the bottom panels showing virus alone.
Statistics. Statistical comparisons were carried out by a Student's paired, two-tailed t-test or ANOVA with a Tukey's post hoc test. ANOVA was used for multiple comparisons to a single control.
RESULTS

Further modifications of SP-D NCRD.
Previous crystallographic analysis of the SP-D lectin domain showed that Asp325 defines a ridge adjacent to the saccharide binding pocket of SP-D (6, 9). We hypothesized that the side chain might limit access of certain glycans to the lectin site and that substitution of aspartate with a residue having a shorter side chain would increase binding to viral glycans and increase antiviral activity. Consistent with this hypothesis, we recently demonstrated enhanced binding of D325A to Phil82 IAV and purified Phil82 HA (7). However, unpublished studies also demonstrated enhanced interactions of D325A with hydrophobic supports, suggesting that substitution of alanine might be contributing to enhanced viral binding by virtue of its hydrophobic character.
Computational modeling suggested that serine would similarly eliminate steric constraints while preserving a hydrophilic environment at position 325. The analysis also suggested that substitution of valine would permit binding while increasing hydrophobicity at this site. This was the case with Arg 343, for which a valine or isoleucine substitution conferred more activity than alanine (5). Notably, D325S resembled D325A in its capacity to neutralize the seasonal H1N1 NY01 IAV (Fig. 1A) . By contrast, D325V had less antiviral activity than D325A (data not shown). The antiviral activity of D325A and D325S was significantly greater than that of wild-type NCRD (Fig.  1A) ; however, their activity was modest compared with that of the double-mutant D325AϩR343V (Fig. 1A) . We next combined the D325S substitution with the R343V substitution. This mutant, like D325AϩR343V, had significantly increased virus-neutralizing activity against seasonal IAV strains compared with D325S or R343V mutants. The neutralizing activity of D325SϩR343V against the seasonal strains NY01 H1N1 and Phil82 H3N2 was similar to that of D325AϩR343V (Fig.  1, A and B) . Infectivity of NY01 H1N1 was fully inhibited by 5 g/ml of D325AϩR343V or D325SϩR343V (lines overlap in Fig. 1A ). For testing against the Phil82 strain, lower concentrations of NCRDs were used. Both of the double-mutant NCRDs showed 50% inhibition of infectivity of Phil82 at ϳ50 ng/ml, which is comparable to the activity of full-length SP-D and substantially greater than the activity of the homologous collectin SP-A or MBL for this strain (15, 29) . D325SϩR343V also had comparable HA inhibitory activity for Phil82 with D325AϩR343V (see Table 2 ).
D325AϩR343V also had strong activity against the glycosylation mutant Braz78BS H1N1 and Phil82BS H3N2 strains, which were not measurably inhibited by wild-type NCRD (Table 2 ). These strains were derived by repeated culture in the presence of bovine serum and are partially resistant to lectinbased inhibition by SP-D, MBL, or bovine conglutinin owing to the loss of HA glycan attachment sites at N104 (for H1N1) or N165 (for H3N2) (10) .
D325SϩR343V has increased antiviral activity against the Aichi68 H3N2 pandemic strain and confers protection against this strain in mice. The Aichi68 H3N2 HA lacks a glycan attachment site at position 144, which is present on Phil82 and Phil82BS. As shown in Table 2 , D325AϩR343V and D325SϩR343V had increased HA inhibitory activity for Aichi68 compared with R343V. Of interest, D325SϩR343V had significantly greater HA inhibiting activity than D325AϩR343V. Again, wild-type NCRD did not inhibit this strain. We recently reported that D325Aϩ R343V has significantly greater neutralizing activity for Aichi68 compared with native SP-D dodecamers, native SP-A, or R343V and that wild-type SP-D NCRD does not inhibit this strain (8) . As shown in Fig. 2 , D325SϩR343V had significantly greater neutralizing activity than D325AϩR343V for Aichi68 in MDCK or HTBE cells. Figure 3 shows that D325AϩR343V and D325Sϩ R343V had marked aggregating activity for the Aichi68 strain as assessed by light transmission assays. Figure 4 shows that these viral aggregates were visualized by confocal microscopy as well.
Note that in the control image (virus alone), or the image in which virus was pretreated with wild-type NCRD, many more cellassociated viral particles were present than in images with D325AϩR343V or D325SϩR343V. Seasonal H3N2 strains generally fail to cause mortality in mice. In contrast, the Aichi68 pandemic H3N2 was lethal for mice (Fig. 5) . Coadminstration of the virus with wild-type NCRD did not reduce mortality in these mice. In contrast, D325SϩR343V reduced mortality. The improvement in mortality was accompanied by decreased weight loss and reduced viral titers at day 3. Hence, D325SϩR343V conferred added protection even in the presence of endogenous wild-type SP-D in these mice.
D325AϩR343V and D325SϩR343V can neutralize pandemic strains of H1N1. As shown in Fig. 6A , D325AϩR343V and D325SϩR343V had significant neutralizing activity against the Cal09 strain of IAV. R343V had significant antiviral activity as well, which also exceeded that of full-length SP-D or wild-type NCRD, but was less than that of the double mutants. Full-length SP-D or wild-type NCRD did not significantly inhibit this viral strain at 5 or 10 g/ml. Figure 6B confirms that the ability of D325AϩR343V to inhibit Cal09 is abrogated by addition of maltose, indicating that the mechanism of inhibition is that of a ␤-inhibitor.
The ability of R343V and D325AϩR343V to inhibit Cal09 IAV was confirmed by use of a quantitative RT-PCR assay detecting RNA encoding the viral M protein (Fig. 7) . The advantages of this assay are that it can analyze the effects of the NCRDs on initial viral uptake by epithelial cells as well as on viral mRNA synthesis and release into the cell supernatant after 24 h. Cal09 IAV that was preincubated with 0.5 or 5 g/ml of D325AϩR343V prior to addition to MDCK cells resulted in significantly reduced viral uptake after 45 min of infection (Fig. 7, A and B) . R343V at the 5 g/ml concentration reduced cell-associated viral RNA at 45 min (Fig. 7B) . Wildtype NCRD did not alter internalization of viral RNA in these experiments. At 24 h after infection (Fig. 7, C and D) , both R343V and D325AϩR343V caused significant reduction in both cell-associated and supernatant viral RNA, whereas wildtype NCRD did not.
To determine the role of viral envelope proteins in inhibition of pandemic IAV by the NCRDs, we utilized two other recombinant strains of IAV that contained either the HA alone or the HA and NA of the Mex09 H1N1 strain (closely related to Cal09) in conjunction with the other gene segments from the seasonal NY01 strain. As shown in Fig. 8, A and B, these strains were more sensitive to inhibition by D325AϩR343V or D325SϩR343V than to wild-type NCRD, R343V, or SP-D. In contrast to intact Cal09 strains, native SP-D was able to cause partial inhibition of these recombinant strains.
As a further test of activity against H1N1 pandemic IAV strains we tested the ability of D325AϩR343V and wild-type NCRD to inhibit a recombinant viral strain containing the HA of 1918 H1N1 with the other genes derived from seasonal H1N1. These assays were performed in a BSL3 facility and infectivity was assessed by plaque assay. D325AϩR343V reduced viral plaques from a control of 27 plaques to 12.3 Ϯ 1.7 plaques at a concentration of 123 ng/ml (n ϭ 3). In contrast, 1.98 g/ml of wild-type NCRD was needed to reduce plaque numbers to a similar extent (i.e., from 25 plaques in control to 17 Ϯ 2). Hence, D325AϩR343V had ϳ1,000-fold greater activity in this assay than wild-type NCRD.
DISCUSSION
Our initial goal for these studies was to understand the structural basis of the strong neutralizing activity of D325AϩR343V for IAV. We tested the effects of other substitutions at the D325 site. We considered that the alanine substitution favored increased binding simply because it was a smaller residue or that it increased binding by allowing increased hydrophobic interactions as in the case of R343. Although the R343V substitution appears to increase access of Experiments were carried out as described for Fig. 1 , but the Cal09 strain was used. The double-mutant NCRDs (D325Aϩ R343V and D325SϩR343V) caused significantly greater inhibition than the other NCRDs or native SP-D in each case. **P Ͻ 0.05; n ϭ 4 -5 experiments. *Infectivity was reduced compared with virus alone. Native SP-D did not reduce infectivity of Cal09 but did inhibit the other strains as indicated. B: control buffer or buffer containing 10 mg/ml of maltose was added during the incubation of D325AϩR343V and Cal09, followed by addition of these samples to cells. &Maltose significantly reduced the inhibitory activity of D325AϩR343V (P Ͻ 0.05; n ϭ 4). certain glycans to the lectin site and to accommodate alternative binding orientations, there is a clear requirement for a hydrophobic residue at this position (5) . Our present studies strongly support the hypothesis that the Asp325 side chain normally limits access of viral glycans to the lectin site of wild-type SP-D. Substitutions with alanine or serine showed modestly enhanced interactions with highly glycosylated seasonal strains of IAV, whereas D325V showed no enhancement. These results can be explained by steric constraints that favor smaller residues. These effects were greatly increased when combined with the R343V mutation such that the D325SϩR343V double mutant has antiviral activities comparable to D325Aϩ R343V for some strains and increased activity for the Aichi68 strain.
Aichi68 H3N2 is a strain isolated during the 1968 pandemic in which the H3N2 subtype was introduced into the human population. As shown in Table 1 , this strain has one predicted glycan at the top of the HA head (position 165) and one on the side of the HA head (position 81). We have previously shown that glycan 165 on Phil82 is predominantly high mannose (7). It appears that the presence of this glycan renders Aichi68 somewhat more sensitive to inhibition by native SP-D than the 2009 pandemic H1N1 strains; however, Aichi68 is still relatively resistant compared with more recent seasonal H3N2 strains such as Phil82 (e.g., the mean 50% neutralizing concentration for Aichi68 is 500 ng/ml compared with 3 ng/ml for Phil82). We recently reported that D325AϩR343V had increased neutralizing activity of Aichi68 compared with native SP-D or SP-A (8). Using molecular dynamic simulations, we showed that this increased neutralizing activity relates to an increased ability of D325AϩR343V to occlude the sialic acid binding site of the Aichi68 HA compared with wild-type NCRD (8) . In addition, these and prior studies indicated an increased ability of the R343V and D325AϩR343V to crosslink HA molecules on the basis of its distinctive binding orientation to the HA after attaching to glycan 165 (5, 7). We as assessed by quantitative RT-PCR. Influenza A virus (IAV; Phil82) was preincubated with NCRDs as described in Fig. 1 now extend upon these studies to show that D325AϩR343V and D325SϩR343V can markedly aggregate Aichi68 (Figs. 3  and 4) . The effect of this aggregation on the basis of our confocal microscopy studies is to markedly reduce the number of viral particles binding to epithelial cells. Of note, D325SϩR343V had greater HA inhibiting and neutralizing activity for Aichi68 than D325AϩR343V and it also protected DBA2J mice from mortality caused by this viral strain.
The most important and novel finding of this paper is that the double-mutant NCRDs not only increase activity against seasonal strains of IAV and the pandemic H3N2 Aichi strain, they also have the capacity to neutralize H1N1 pandemic strains that have no N-linked glycan attachments on the HA head and are not at all inhibited by native SP-D. The mechanism of inhibition of Cal09 includes reduced viral uptake as revealed by our quantitative PCR studies (Fig. 7) . We propose that the doublemutant NCRDs can bind to the single HA glycan site at position 104 on the side of the HA head in a way that is not possible for wild-type NCRD and that cannot be offset by the dodecameric structure of the native protein.
R343V was also able to inhibit pandemic H1N1, albeit to a lesser extent. Through use of the recombinant viral strains containing just the HA, or HA and NA, of a 2009 pandemic strain, it appears that variations in binding to HA account mainly for the ability of the mutant NCRDs to inhibit 2009 H1N1. It is possible, however, that the NA or other genes of the pandemic strains differs as well from the seasonal NA (e.g., of NY01) because the strain containing just the 2009 HA is partially inhibited by wild-type, native SP-D. We and others have previously shown that SP-D can bind to the NA of seasonal IAV (22, 24) . However, these prior studies with seasonal IAV strains have suggested that binding to viral NA does not contribute to neutralizing activity of SP-D (22, 24) . We also show that D325AϩR343V can inhibit infectivity of a viral strain containing the HA of the 1918 H1N1. Previous studies showed that wild-type, native SP-D does not inhibit this strain in vitro or in vivo (21) . The 1918 HA has high homology with the 2009 HA (including having the same glycan attachment sites) (23) . Therefore, these findings provide further validation that D325AϩR343V is able to bind to and inhibit H1 strains with this HA structure.
It is notable that the concentrations of D325AϩR343V or D325SϩR343V needed to inhibit Aichi68 were less than those needed to inhibit Cal09 (e.g., compare Fig. 2 and Fig. 6 ). We conclude from this that the glycan composition of Aichi68 is more favorable for lectin-based inhibition than that of Cal09. As noted, Cal09 has one glycan on the side of the HA head, whereas Aichi68 has a glycan on the top of the head (165) and one on the side (81). The composition of glycan 104 on Cal09 (or the 1918 HA) has not been determined as yet. Further studies to determine the composition of this glycan and to model binding of lectins to it will be very revealing regarding the mechanism of action of wild-type and mutant collectins.
Conclusion. A key novel observation of this study is that modifications of residues flanking the lectin site of SP-D confer neutralizing activity against pandemic IAV strains, including H1N1 strains from 1918 and 2009. We initially suspected that enhancing the lectin activity of SP-D would not result in inhibition of these strains because they are not inhibited by native SP-D. In addition, other early H1N1 isolates (PR-8 and WSN from the 1930s) are not inhibited by SP-D or D325AϩR343V (7, 15) . However, the PR-8 and WSN strains are both highly mouse-adapted and completely lack N-linked glycans on the top or side of the head regions of their HA (1). In these regards, these strains are not representative of human pandemic strains. The double-mutant NCRDs presumably can bind to the single glycan on the side of the head region of the pandemic H1N1 strains. We also provide evidence for the mechanism of action of the double-mutant NCRDs against pandemic H1N1 and H3N2. Our findings suggest that modified host defense lectins can inhibit major pandemic IAV strains. Given the protective activity of D325SϩR343V against Aichi68 H3N2 in mice, such lectins should continue to be explored as therapeutic options for IAV.
